CFDA Issues Warning Against Allopurinol Gout Drug Over Side Effects
This article was originally published in PharmAsia News
The China FDA issued a warning to the public against taking the allopurinol drug for treating gout, developed in the U.S. as Zyloprim by Prometheus Labs and Aloprin injectables by Mylan Laboratories.
You may also be interested in...
US FDA adds brucellosis, opisthorchiasis and paragonimiasis to the list of qualifying diseases but declines to include clonorchiasis and coccidioidomycosis, finding a significant market in developed nations for treatments or vaccines addressing the two conditions.
Mallinckrodt’s Terlipressin Narrowly Clears US FDA Panel As Need For Liver Treatment Outweighs Safety Worries
Advisory committee votes 8-7 to recommend approval for terlipressin to treat HRS-1 but is critical of Mallinckrodt’s plan to mitigate the risk of respiratory failure.
ECHA Committee Stops Short Of Advising Derogation Or Deadline Extension For Cosmetic Microplastic Ban
Uncertainties related to leave-on cosmetics’ microplastic releases to the environment, and the costs industry would face in removing microplastic from such products, “do not allow for SEAC to conclude whether other options would be more appropriate than a ban,” the European Chemicals Agency’s Socio-Economic Analysis Committee says in a 1 July draft opinion.